Genscript Biotech マネジメント
マネジメント 基準チェック /14
Genscript Biotechの CEO はWeihui Shaoで、 Jul2021年に任命され、 の在任期間は 3.33年です。 の年間総報酬は$ 2.48Mで、 14.3%給与と85.7%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.034%を直接所有しており、その価値はHK$ 7.65M 。経営陣と取締役会の平均在任期間はそれぞれ3.6年と1.7年です。
主要情報
Weihui Shao
最高経営責任者
US$2.5m
報酬総額
| CEO給与比率 | 14.3% |
| CEO在任期間 | 3.3yrs |
| CEOの所有権 | 0.03% |
| 経営陣の平均在職期間 | 3.6yrs |
| 取締役会の平均在任期間 | 1.7yrs |
経営陣の近況
Recent updates
Market Still Lacking Some Conviction On Genscript Biotech Corporation (HKG:1548)
Nov 19
Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?
Oct 01What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?
Sep 16After Leaping 44% Genscript Biotech Corporation (HKG:1548) Shares Are Not Flying Under The Radar
Aug 02Slammed 28% Genscript Biotech Corporation (HKG:1548) Screens Well Here But There Might Be A Catch
Jun 05A Look At The Fair Value Of Genscript Biotech Corporation (HKG:1548)
May 10Is Genscript Biotech (HKG:1548) A Risky Investment?
Apr 13Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%
Mar 13Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Jan 26Is Genscript Biotech (HKG:1548) A Risky Investment?
Nov 21Is Genscript Biotech (HKG:1548) A Risky Investment?
Aug 22Time To Worry? Analysts Just Downgraded Their Genscript Biotech Corporation (HKG:1548) Outlook
Apr 04Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report
Apr 03Is Genscript Biotech (HKG:1548) A Risky Investment?
Apr 02Genscript Biotech Corporation (HKG:1548) Shares Could Be 25% Below Their Intrinsic Value Estimate
Feb 07What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?
Dec 14Genscript Biotech Corporation (HKG:1548) Shares Could Be 22% Below Their Intrinsic Value Estimate
Nov 09Is Genscript Biotech (HKG:1548) Using Debt Sensibly?
Oct 22Health Check: How Prudently Does Genscript Biotech (HKG:1548) Use Debt?
Apr 03Does Genscript Biotech (HKG:1548) Have A Healthy Balance Sheet?
Oct 03Is It Time To Consider Buying Genscript Biotech Corporation (HKG:1548)?
Sep 07Estimating The Fair Value Of Genscript Biotech Corporation (HKG:1548)
Aug 16Is It Time To Consider Buying Genscript Biotech Corporation (HKG:1548)?
Jun 03Is Genscript Biotech Corporation (HKG:1548) Trading At A 49% Discount?
May 13Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?
Apr 16Could The Genscript Biotech Corporation (HKG:1548) Ownership Structure Tell Us Something Useful?
Mar 20Are Insiders Selling Genscript Biotech Corporation (HKG:1548) Stock?
Feb 13
Did The Underlying Business Drive Genscript Biotech's (HKG:1548) Lovely 753% Share Price Gain?
Jan 09CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$177m |
| Mar 31 2024 | n/a | n/a | -US$136m |
| Dec 31 2023 | US$2m | US$353k | -US$95m |
報酬と市場: Weihuiの 総報酬 ($USD 2.48M ) は、 Hong Kong市場 ($USD 481.50K ) の同規模の企業の平均を上回っています。
報酬と収益: Weihuiの報酬と会社の業績を比較するにはデータが不十分です。
CEO（最高経営責任者
Weihui Shao (44 yo)
3.3yrs
在職期間
US$2,477,000
報酬
Ms. Weihui Shao is Chief Operating Officer of Genscript Biotech Corporation from July 08, 2021 and serves as its Rotating Chief Executive Officer since January 01, 2023. She joined the Genscript Biotech Co...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Executive Chairman | 9.3yrs | US$495.00k | 0.013% HK$ 3.0m | |
| CEO & COO | 3.3yrs | US$2.48m | 0.034% HK$ 7.7m | |
| Co-Founder | 22.8yrs | US$659.00k | 0.036% HK$ 8.3m | |
| Co-Founder & Non-Executive Director | no data | データなし | 0.030% HK$ 6.8m | |
| Co-Founder & Executive Director | 1.9yrs | US$531.00k | データなし | |
| Chief Strategy Officer & Executive Director | 4yrs | US$320.00k | 0.054% HK$ 12.2m | |
| Chief Financial Officer | 3.9yrs | データなし | データなし | |
| Chief Marketing Officer for GenScript Life Science Group | no data | データなし | データなし |
3.6yrs
平均在職期間
56yo
平均年齢
経験豊富な経営陣: 1548の経営陣は 経験豊富 であると考えられます ( 3.6年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Executive Chairman | 9.3yrs | US$495.00k | 0.013% HK$ 3.0m | |
| Co-Founder | 9.5yrs | US$659.00k | 0.036% HK$ 8.3m | |
| Co-Founder & Non-Executive Director | 9.5yrs | データなし | 0.030% HK$ 6.8m | |
| Co-Founder & Executive Director | 2.5yrs | US$531.00k | データなし | |
| Chief Strategy Officer & Executive Director | 4yrs | US$320.00k | 0.054% HK$ 12.2m | |
| Member of Advisory Board | less than a year | データなし | データなし | |
| Member of Advisory Board | 5.2yrs | データなし | データなし | |
| Independent Non-Executive Director | less than a year | データなし | データなし | |
| Member of Scientific Advisory Board | less than a year | データなし | データなし | |
| Independent Non-Executive Director | less than a year | データなし | データなし | |
| Independent Non-Executive Director | less than a year | データなし | データなし | |
| Independent Non-Executive Director | less than a year | データなし | データなし |
1.7yrs
平均在職期間
61.5yo
平均年齢
経験豊富なボード: 1548の 取締役会 は 経験豊富 ではない ( 1.7年の平均在任期間) ため、新しい取締役会が必要であると考えられます。